[
  {
    "resultsSection": {},
    "studyId": "NCT00147329"
  },
  {
    "resultsSection": {},
    "studyId": "NCT00230529"
  },
  {
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Tapinarof (DMVT-505) Cream Group",
            "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
          },
          {
            "id": "FG001",
            "title": "Vehicle Cream Group",
            "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "343"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "172"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "282"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "142"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "61"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "30"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Tapinarof (DMVT-505) Cream Group",
            "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
          },
          {
            "id": "BG001",
            "title": "Vehicle Cream Group",
            "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "groupId": "BG000",
                "value": "343"
              },
              {
                "groupId": "BG001",
                "value": "172"
              },
              {
                "groupId": "BG002",
                "value": "515"
              }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "50.0",
                        "spread": "13.07"
                      },
                      {
                        "groupId": "BG001",
                        "value": "50.0",
                        "spread": "13.67"
                      },
                      {
                        "groupId": "BG002",
                        "value": "50.0",
                        "spread": "13.26"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "155"
                      },
                      {
                        "groupId": "BG001",
                        "value": "70"
                      },
                      {
                        "groupId": "BG002",
                        "value": "225"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "188"
                      },
                      {
                        "groupId": "BG001",
                        "value": "102"
                      },
                      {
                        "groupId": "BG002",
                        "value": "290"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "43"
                      },
                      {
                        "groupId": "BG001",
                        "value": "23"
                      },
                      {
                        "groupId": "BG002",
                        "value": "66"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "300"
                      },
                      {
                        "groupId": "BG001",
                        "value": "148"
                      },
                      {
                        "groupId": "BG002",
                        "value": "448"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "2"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "25"
                      },
                      {
                        "groupId": "BG001",
                        "value": "21"
                      },
                      {
                        "groupId": "BG002",
                        "value": "46"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "12"
                      },
                      {
                        "groupId": "BG001",
                        "value": "6"
                      },
                      {
                        "groupId": "BG002",
                        "value": "18"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "300"
                      },
                      {
                        "groupId": "BG001",
                        "value": "138"
                      },
                      {
                        "groupId": "BG002",
                        "value": "438"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      },
                      {
                        "groupId": "BG001",
                        "value": "3"
                      },
                      {
                        "groupId": "BG002",
                        "value": "6"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Physicians Global Assessment",
            "description": "The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease.",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "0 - Clear",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "1 - Almost Clear",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "2 - Mild",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "28"
                      },
                      {
                        "groupId": "BG001",
                        "value": "15"
                      },
                      {
                        "groupId": "BG002",
                        "value": "43"
                      }
                    ]
                  },
                  {
                    "title": "3 - Moderate",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "288"
                      },
                      {
                        "groupId": "BG001",
                        "value": "144"
                      },
                      {
                        "groupId": "BG002",
                        "value": "432"
                      }
                    ]
                  },
                  {
                    "title": "4 - severe",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "27"
                      },
                      {
                        "groupId": "BG001",
                        "value": "13"
                      },
                      {
                        "groupId": "BG002",
                        "value": "40"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Psoriasis Area and Severity Index",
            "description": "The Psoriasis Area and Severity Index (PASI) scoring system combines lesion severity and extent of affected area into 1 score: 0 (no disease) to 72 (maximal disease). 4 areas (head, arms, trunk, and legs) are each assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe and percent of skin involved using a 6-point scale were 6 is worse. Scores are multiplied by a weighted factor for each region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "units on a scale",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "9.05",
                        "spread": "3.676"
                      },
                      {
                        "groupId": "BG001",
                        "value": "9.27",
                        "spread": "4.016"
                      },
                      {
                        "groupId": "BG002",
                        "value": "9.12",
                        "spread": "3.791"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Percent Body Surface Area",
            "description": "The handprint method was used to assess BSA with psoriasis, where the full palmar hand of the participant represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \\[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\\]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "Percent",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "7.8",
                        "spread": "4.39"
                      },
                      {
                        "groupId": "BG001",
                        "value": "7.3",
                        "spread": "4.14"
                      },
                      {
                        "groupId": "BG002",
                        "value": "7.6",
                        "spread": "4.31"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation",
            "description": "The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "percentage of subjects",
            "timeFrame": "Baseline to Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Tapinarof (DMVT-505) Cream Group",
                "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
              },
              {
                "id": "OG001",
                "title": "Vehicle Cream Group",
                "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "343"
                  },
                  {
                    "groupId": "OG001",
                    "value": "172"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "40.2",
                        "spread": "2.82"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.3",
                        "spread": "1.99"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "<0.0001",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Risk Ratio (RR)",
                "paramValue": "6.10",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percent of Subjects With \u2265 75% Improvement in Psoriasis Area and Severity Index (PASI) From Baseline at Week 12. Analyses Were Done Using Multiple Imputation.",
            "description": "The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\\<10%), 2 = (10-\\<30%), 3 = (30-\\<50%), 4 = (50 -\\<70%), 5 = (70-\\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "percentage of subjects",
            "timeFrame": "Baseline to Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Tapinarof (DMVT-505) Cream Group",
                "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
              },
              {
                "id": "OG001",
                "title": "Vehicle Cream Group",
                "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "343"
                  },
                  {
                    "groupId": "OG001",
                    "value": "172"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "47.6",
                        "spread": "2.81"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.9",
                        "spread": "2.01"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "<0.0001",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Risk Ratio (RR)",
                "paramValue": "6.53",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percent of Subjects With a PGA Score of 0 or 1 at Week 12. Analyses Were Done Using Multiple Imputation.",
            "description": "The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. A static 5-point scale is used to grade lesions on the clinical characteristics of erythema, scaling, and plaque thickness/elevation. The PGA ranges from 0 to 4, and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease. Analyses were done using multiple imputation.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "percentage of subjects",
            "timeFrame": "Baseline to Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Tapinarof (DMVT-505) Cream Group",
                "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
              },
              {
                "id": "OG001",
                "title": "Vehicle Cream Group",
                "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "343"
                  },
                  {
                    "groupId": "OG001",
                    "value": "172"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "43.6",
                        "spread": "2.85"
                      },
                      {
                        "groupId": "OG001",
                        "value": "8.1",
                        "spread": "2.21"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "<0.0001",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Risk Ratio (RR)",
                "paramValue": "4.55",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Mean Change in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 12",
            "description": "Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage \\[Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)\\]. Estimates of the % involvement in each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "Mean change from Baseline",
            "timeFrame": "Baseline to Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Tapinarof (DMVT-505) Cream Group",
                "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
              },
              {
                "id": "OG001",
                "title": "Vehicle Cream Group",
                "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "343"
                  },
                  {
                    "groupId": "OG001",
                    "value": "172"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-4.22",
                        "spread": "0.367"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0.10",
                        "spread": "0.448"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "<0.0001",
                "statisticalMethod": "ANCOVA",
                "paramType": "Least squares mean difference",
                "paramValue": "-4.32",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Percent of Subjects With \u226590% Improvement in PASI Score From Baseline to Week 12. Analyses Were Done Using Multiple Imputation.",
            "description": "The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\\<10%), 2 = (10-\\<30%), 3 = (30-\\<50%), 4 = (50 -\\<70%), 5 = (70-\\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores. Analyses were done using multiple imputation.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "percentage of subjects",
            "timeFrame": "Baseline to Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Tapinarof (DMVT-505) Cream Group",
                "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily"
              },
              {
                "id": "OG001",
                "title": "Vehicle Cream Group",
                "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "343"
                  },
                  {
                    "groupId": "OG001",
                    "value": "172"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "20.9",
                        "spread": "2.28"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2.5",
                        "spread": "1.21"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG001"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "<0.0001",
                "statisticalMethod": "Cochran-Mantel-Haenszel",
                "paramType": "Risk Ratio (RR)",
                "paramValue": "7.25",
                "ciNumSides": "TWO_SIDED"
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "1",
        "timeFrame": "Subject duration: 12 weeks of treatment and 4 week follow-up for subjects not enrolled in the long-term extension study (DMVT-505-3003)",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Tapinarof (DMVT-505) Cream Group",
            "description": "Tapinarof cream, 1%, applied once daily\n\nTapinarof: Tapinarof cream, 1%, applied once daily.\n\nAll SAEs were deemed unrelated to treatment with tapinarof cream, 1%.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 343,
            "seriousNumAffected": 7,
            "seriousNumAtRisk": 343,
            "otherNumAffected": 123,
            "otherNumAtRisk": 343
          },
          {
            "id": "EG001",
            "title": "Vehicle Cream Group",
            "description": "Vehicle cream applied once daily\n\nVehicle Cream: Vehicle cream applied once daily.\n\nAll SAEs were deemed unrelated to treatment with tapinarof cream, 1%.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 172,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 172,
            "otherNumAffected": 28,
            "otherNumAtRisk": 172
          }
        ],
        "seriousEvents": [
          {
            "term": "Coronary artery stenosis",
            "organSystem": "Cardiac disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Pancreatitis",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Cholelithiasis",
            "organSystem": "Hepatobiliary disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Appendicitis",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Headache",
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Nerve compression",
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Nephrolithiasis",
            "organSystem": "Renal and urinary disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          }
        ],
        "otherEvents": [
          {
            "term": "Diarrhoea",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 4,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Application site pruritus",
            "organSystem": "General disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 4,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Folliculitis",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 59,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Upper respiratory tract infection",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 12,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 8,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Nasopharyngitis",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 14,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 5,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Bronchitis",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 6,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Sinusitis",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 6,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Urinary tract infection",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 5,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 2,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Influenza",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 5,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Glucose tolerance impaired",
            "organSystem": "Metabolism and nutrition disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 0,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 2,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Back pain",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 2,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 3,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Headache",
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 13,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Cough",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 5,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Dermatitis contact",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 18,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Pruritus",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 7,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 2,
                "numAtRisk": 172
              }
            ]
          },
          {
            "term": "Dermatitis",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 5,
                "numAtRisk": 343
              },
              {
                "groupId": "EG001",
                "numAffected": 1,
                "numAtRisk": 172
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": true
        },
        "pointOfContact": {
          "title": "Clinical Lead, Late-Stage Clinical Development",
          "organization": "Organon and Co",
          "email": "pdrl@organon.com",
          "phone": "551-430-6000"
        }
      }
    },
    "studyId": "NCT03983980"
  },
  {
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Clobex Spray",
            "description": "Clobex Spray"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "28"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "28"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Clobex Spray",
            "description": "Clobex Spray"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "groupId": "BG000",
                "value": "28"
              }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "55.2",
                        "spread": "12.8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "18"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "10"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "28"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Subject Reported Target Lesion Severity Score.",
            "description": "Subject reported mean scores of the target lesion numeric rating scale (TL-NRS; scale of 0 (no psoriasis) to 10 (very severe psoriasis)) at end of study.",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "2 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Clobex Spray",
                "description": "Clobex Spray"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "28"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "4.0",
                        "spread": "2.5"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Investigator Reported Target Lesion Severity Score",
            "description": "Investigator reported mean scores of the target lesion numeric rating scale (TL-NRS; scale of 0 (no psoriasis) to 10 (very severe psoriasis)) at end of study",
            "reportingStatus": "POSTED",
            "paramType": "MEAN",
            "dispersionType": "Standard Deviation",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "2 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Clobex Spray",
                "description": "Clobex Spray"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "28"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3.3",
                        "spread": "2.1"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "From baseline up to Day 15",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Clobex Spray",
            "description": "Clobex Spray",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 28,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 28,
            "otherNumAffected": 4,
            "otherNumAtRisk": 28
          }
        ],
        "otherEvents": [
          {
            "term": "Erythema",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          },
          {
            "term": "Pruritus",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          },
          {
            "term": "Skin exfoliation",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          },
          {
            "term": "Skin plaque",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          },
          {
            "term": "Joint swelling",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 28
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Senior Clinical Project Manager",
          "organization": "Galderma Laboratories, L.P.",
          "email": "jay.mashburn@galderma.com",
          "phone": "817-961-5000"
        }
      }
    },
    "studyId": "NCT01893567"
  },
  {
    "resultsSection": {},
    "studyId": "NCT05855967"
  },
  {
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "BCD-085 Q2W",
            "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q2W: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
          },
          {
            "id": "FG001",
            "title": "BCD-085 Q4W",
            "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q4W: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54."
          },
          {
            "id": "FG002",
            "title": "Placebo",
            "description": "Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50.\n\nPlacebo: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
          }
        ],
        "periods": [
          {
            "title": "Weeks 0-12",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "85"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "84"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "44"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "85"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "82"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "43"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "2"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "1"
                  }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "1"
                  }
                ]
              },
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "0"
                  }
                ]
              }
            ]
          },
          {
            "title": "Weeks 12-54",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "85"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "82"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "43"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "82"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "78"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "41"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "3"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "4"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "2"
                  }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "3"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "1"
                  }
                ]
              },
              {
                "type": "Pregnancy",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "0"
                  }
                ]
              },
              {
                "type": "Adverse Event",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "2"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "1"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "populationDescription": "All randomized subjects",
        "groups": [
          {
            "id": "BG000",
            "title": "BCD-085 Q2W",
            "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q2W: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
          },
          {
            "id": "BG001",
            "title": "BCD-085 Q4W",
            "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q4W: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54."
          },
          {
            "id": "BG002",
            "title": "Placebo",
            "description": "Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50.\n\nPlacebo: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
          },
          {
            "id": "BG003",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "groupId": "BG000",
                "value": "85"
              },
              {
                "groupId": "BG001",
                "value": "84"
              },
              {
                "groupId": "BG002",
                "value": "44"
              },
              {
                "groupId": "BG003",
                "value": "213"
              }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEDIAN",
            "dispersionType": "INTER_QUARTILE_RANGE",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "42",
                        "lowerLimit": "35",
                        "upperLimit": "49"
                      },
                      {
                        "groupId": "BG001",
                        "value": "41.5",
                        "lowerLimit": "32",
                        "upperLimit": "53"
                      },
                      {
                        "groupId": "BG002",
                        "value": "39",
                        "lowerLimit": "33",
                        "upperLimit": "53"
                      },
                      {
                        "groupId": "BG003",
                        "value": "42",
                        "lowerLimit": "33",
                        "upperLimit": "52"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "22"
                      },
                      {
                        "groupId": "BG001",
                        "value": "26"
                      },
                      {
                        "groupId": "BG002",
                        "value": "9"
                      },
                      {
                        "groupId": "BG003",
                        "value": "57"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "63"
                      },
                      {
                        "groupId": "BG001",
                        "value": "58"
                      },
                      {
                        "groupId": "BG002",
                        "value": "35"
                      },
                      {
                        "groupId": "BG003",
                        "value": "156"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "85"
                      },
                      {
                        "groupId": "BG001",
                        "value": "84"
                      },
                      {
                        "groupId": "BG002",
                        "value": "44"
                      },
                      {
                        "groupId": "BG003",
                        "value": "213"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Weight",
            "paramType": "MEDIAN",
            "dispersionType": "INTER_QUARTILE_RANGE",
            "unitOfMeasure": "kg",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "87.3",
                        "lowerLimit": "75",
                        "upperLimit": "96.1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "89.5",
                        "lowerLimit": "78",
                        "upperLimit": "98"
                      },
                      {
                        "groupId": "BG002",
                        "value": "83.5",
                        "lowerLimit": "70",
                        "upperLimit": "95"
                      },
                      {
                        "groupId": "BG003",
                        "value": "87.3",
                        "lowerLimit": "75",
                        "upperLimit": "97"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Height",
            "paramType": "MEDIAN",
            "dispersionType": "INTER_QUARTILE_RANGE",
            "unitOfMeasure": "cm",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "178",
                        "lowerLimit": "170",
                        "upperLimit": "184"
                      },
                      {
                        "groupId": "BG001",
                        "value": "176",
                        "lowerLimit": "168",
                        "upperLimit": "182"
                      },
                      {
                        "groupId": "BG002",
                        "value": "175.5",
                        "lowerLimit": "168",
                        "upperLimit": "180"
                      },
                      {
                        "groupId": "BG003",
                        "value": "176",
                        "lowerLimit": "169",
                        "upperLimit": "182"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Body Surface Area Affected by Psoriasis (BSA)",
            "description": "The body surface area affected by psoriasis (BSA) is estimated with the palm rule. The area of the human palm without fingers corresponds to about 1% of the body surface.",
            "paramType": "MEDIAN",
            "dispersionType": "INTER_QUARTILE_RANGE",
            "unitOfMeasure": "percentage of BSA",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "20",
                        "lowerLimit": "13",
                        "upperLimit": "42"
                      },
                      {
                        "groupId": "BG001",
                        "value": "22",
                        "lowerLimit": "14.5",
                        "upperLimit": "43"
                      },
                      {
                        "groupId": "BG002",
                        "value": "22.5",
                        "lowerLimit": "13",
                        "upperLimit": "44"
                      },
                      {
                        "groupId": "BG003",
                        "value": "22",
                        "lowerLimit": "14",
                        "upperLimit": "43"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "PASI score",
            "description": "The Psoriasis Area and Severity Index (PASI) allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease).",
            "paramType": "MEDIAN",
            "dispersionType": "INTER_QUARTILE_RANGE",
            "unitOfMeasure": "score",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "18.4",
                        "lowerLimit": "14.2",
                        "upperLimit": "27"
                      },
                      {
                        "groupId": "BG001",
                        "value": "17.9",
                        "lowerLimit": "15.1",
                        "upperLimit": "28.6"
                      },
                      {
                        "groupId": "BG002",
                        "value": "19.7",
                        "lowerLimit": "16.3",
                        "upperLimit": "29.4"
                      },
                      {
                        "groupId": "BG003",
                        "value": "18.6",
                        "lowerLimit": "15",
                        "upperLimit": "28.5"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "sPGA score",
            "description": "The Static Physician Global Assessment (sPGA) scale is used to assess the psoriatic lesions in a certain patient from 0 (clear) to 5 (very severe). Within each area, the severity is estimated by three criteria (induration, desquamation, and erythema).",
            "paramType": "MEDIAN",
            "dispersionType": "INTER_QUARTILE_RANGE",
            "unitOfMeasure": "score",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3",
                        "lowerLimit": "3",
                        "upperLimit": "4"
                      },
                      {
                        "groupId": "BG001",
                        "value": "4",
                        "lowerLimit": "3",
                        "upperLimit": "4"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4",
                        "lowerLimit": "3",
                        "upperLimit": "4"
                      },
                      {
                        "groupId": "BG003",
                        "value": "3",
                        "lowerLimit": "3",
                        "upperLimit": "4"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "\u2022 The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment",
            "description": "The Psoriasis Area and Severity Index (PASI) allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease).\n\nRelative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value) PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement.",
            "populationDescription": "ITT-population (all randomized)",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "BCD-085 Q2W",
                "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q2W: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
              },
              {
                "id": "OG001",
                "title": "BCD-085 Q4W",
                "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q4W: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54."
              },
              {
                "id": "OG002",
                "title": "Placebo",
                "description": "Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50.\n\nPlacebo: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "85"
                  },
                  {
                    "groupId": "OG001",
                    "value": "84"
                  },
                  {
                    "groupId": "OG002",
                    "value": "44"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "66"
                      },
                      {
                        "groupId": "OG001",
                        "value": "70"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "timeFrame": "Weeks 0-12",
        "description": "The safety analysis included the data from all randomized patients.",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "BCD-085 Q2W",
            "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q2W: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 85,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 85,
            "otherNumAffected": 15,
            "otherNumAtRisk": 85
          },
          {
            "id": "EG001",
            "title": "BCD-085 Q4W",
            "description": "Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50.\n\nBCD-085 Q4W: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 84,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 84,
            "otherNumAffected": 13,
            "otherNumAtRisk": 84
          },
          {
            "id": "EG002",
            "title": "Placebo",
            "description": "Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50.\n\nPlacebo: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.\n\nOn Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 44,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 44,
            "otherNumAffected": 8,
            "otherNumAtRisk": 44
          }
        ],
        "seriousEvents": [
          {
            "term": "Pneumonia",
            "organSystem": "Infections and infestations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          }
        ],
        "otherEvents": [
          {
            "term": "Hypertension",
            "organSystem": "Vascular disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Systolic hypertension",
            "organSystem": "Vascular disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Diastolic hypertension",
            "organSystem": "Vascular disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "ECG signs of myocardial ischaemia",
            "organSystem": "Investigations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Upper respiratory tract infection",
            "organSystem": "Infections and infestations",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Tonsillitis",
            "organSystem": "Infections and infestations",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Urinary tract infection",
            "organSystem": "Infections and infestations",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Erythema",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Eczema",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Procedural dizziness",
            "organSystem": "Injury, poisoning and procedural complications",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Abdominal pain",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Haemoglobin increased",
            "organSystem": "Investigations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Thrombocytopenia",
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Leukopenia",
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Neutropenia",
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Lymphocytosis",
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Hyperbilirubinemia",
            "organSystem": "Hepatobiliary disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 4,
                "numAffected": 4,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Aspartate aminotransferase increased",
            "organSystem": "Investigations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Alanine aminotransferase increased",
            "organSystem": "Investigations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Blood cholesterol increased",
            "organSystem": "Investigations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Hyperglycaemia",
            "organSystem": "Metabolism and nutrition disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Blood creatinine increased",
            "organSystem": "Investigations",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Proteinuria",
            "organSystem": "Renal and urinary disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 44
              }
            ]
          },
          {
            "term": "Thermal burn",
            "organSystem": "Injury, poisoning and procedural complications",
            "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 85
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 84
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 44
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictiveAgreement": false
        },
        "pointOfContact": {
          "title": "Nikiforova Aleksandra",
          "organization": "BIOCAD",
          "email": "nikiforovaan@biocad.ru",
          "phone": "+7(812) 380 49 33",
          "phoneExt": "6254"
        }
      }
    },
    "studyId": "NCT03390101"
  },
  {
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "XP23829 400 mg QD (Once Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period\n\nXP23829 400 mg QD: active dose 1"
          },
          {
            "id": "FG001",
            "title": "XP23829 800 mg QD (Once Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period\n\nXP 23829 800 mg QD: active dose 2"
          },
          {
            "id": "FG002",
            "title": "XP23829 400 mg BID (Twice Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period\n\nXP23829 400 mg BID: active dose 3"
          },
          {
            "id": "FG003",
            "title": "Placebo",
            "description": "After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks\n\nPlacebo: control"
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "49"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "55"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "48"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "48"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "29"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "32"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "28"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "33"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "20"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "23"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "20"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "15"
                  }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Adverse Event",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "7"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "8"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "13"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "5"
                  }
                ]
              },
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "8"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "10"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "4"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "8"
                  }
                ]
              },
              {
                "type": "Lost to Follow-up",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "4"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "4"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "2"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "2"
                  }
                ]
              },
              {
                "type": "Protocol Violation",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "0"
                  }
                ]
              },
              {
                "type": "Physician Decision",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "0"
                  }
                ]
              },
              {
                "type": "Subject unable to return for week 16 assessment within Sponsor timelines for study completion",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "1"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG002",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG003",
                    "numSubjects": "0"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "XP23829 400 mg QD (Once Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period\n\nXP23829 400 mg QD: active dose 1"
          },
          {
            "id": "BG001",
            "title": "XP23829 800 mg QD (Once Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period\n\nXP 23829 800 mg QD: active dose 2"
          },
          {
            "id": "BG002",
            "title": "XP23829 400 mg BID (Twice Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period\n\nXP23829 400 mg BID: active dose 3"
          },
          {
            "id": "BG003",
            "title": "Placebo",
            "description": "After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks\n\nPlacebo: control"
          },
          {
            "id": "BG004",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "groupId": "BG000",
                "value": "49"
              },
              {
                "groupId": "BG001",
                "value": "55"
              },
              {
                "groupId": "BG002",
                "value": "48"
              },
              {
                "groupId": "BG003",
                "value": "48"
              },
              {
                "groupId": "BG004",
                "value": "200"
              }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "50.8",
                        "spread": "11.89"
                      },
                      {
                        "groupId": "BG001",
                        "value": "47.7",
                        "spread": "10.55"
                      },
                      {
                        "groupId": "BG002",
                        "value": "51.8",
                        "spread": "13.80"
                      },
                      {
                        "groupId": "BG003",
                        "value": "51.1",
                        "spread": "13.66"
                      },
                      {
                        "groupId": "BG004",
                        "value": "50.3",
                        "spread": "12.49"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "17"
                      },
                      {
                        "groupId": "BG001",
                        "value": "23"
                      },
                      {
                        "groupId": "BG002",
                        "value": "16"
                      },
                      {
                        "groupId": "BG003",
                        "value": "14"
                      },
                      {
                        "groupId": "BG004",
                        "value": "70"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "32"
                      },
                      {
                        "groupId": "BG001",
                        "value": "32"
                      },
                      {
                        "groupId": "BG002",
                        "value": "32"
                      },
                      {
                        "groupId": "BG003",
                        "value": "34"
                      },
                      {
                        "groupId": "BG004",
                        "value": "130"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "12"
                      },
                      {
                        "groupId": "BG001",
                        "value": "7"
                      },
                      {
                        "groupId": "BG002",
                        "value": "11"
                      },
                      {
                        "groupId": "BG003",
                        "value": "1"
                      },
                      {
                        "groupId": "BG004",
                        "value": "31"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "37"
                      },
                      {
                        "groupId": "BG001",
                        "value": "48"
                      },
                      {
                        "groupId": "BG002",
                        "value": "37"
                      },
                      {
                        "groupId": "BG003",
                        "value": "47"
                      },
                      {
                        "groupId": "BG004",
                        "value": "169"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      },
                      {
                        "groupId": "BG003",
                        "value": "1"
                      },
                      {
                        "groupId": "BG004",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "1"
                      },
                      {
                        "groupId": "BG004",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "4"
                      },
                      {
                        "groupId": "BG001",
                        "value": "3"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      },
                      {
                        "groupId": "BG003",
                        "value": "2"
                      },
                      {
                        "groupId": "BG004",
                        "value": "10"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "44"
                      },
                      {
                        "groupId": "BG001",
                        "value": "48"
                      },
                      {
                        "groupId": "BG002",
                        "value": "45"
                      },
                      {
                        "groupId": "BG003",
                        "value": "44"
                      },
                      {
                        "groupId": "BG004",
                        "value": "181"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      },
                      {
                        "groupId": "BG003",
                        "value": "0"
                      },
                      {
                        "groupId": "BG004",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Baseline PASI score",
            "description": "The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.\n\nPASI score assessed at Baseline Visit",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "units on a scale",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "18.32",
                        "spread": "7.413"
                      },
                      {
                        "groupId": "BG001",
                        "value": "18.19",
                        "spread": "7.977"
                      },
                      {
                        "groupId": "BG002",
                        "value": "17.51",
                        "spread": "4.791"
                      },
                      {
                        "groupId": "BG003",
                        "value": "19.13",
                        "spread": "7.671"
                      },
                      {
                        "groupId": "BG004",
                        "value": "18.28",
                        "spread": "7.082"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Baseline sPGA",
            "description": "Score Grade : Definition - 0 Clear: No signs of psoriasis Almost clear: No thickening to minimal plaque elevation; Normal to slight pink coloration/faint erythema; Focal to minimal scaling Mild: Slight elevation/thickening; Pink to light red coloration; Predominantly fine scaling partially or mostly covering lesions Moderate: Clearly distinguishable/distinct thickening; Definite red coloration; Coarse scaling covering most plaques Severe: Marked thickening with hard/sharp edges; Bright to deep dark red coloration; Thick/coarse scaling covering almost all or all lesions\n\nsPGA atbaseline",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "3 Moderate",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "32"
                      },
                      {
                        "groupId": "BG001",
                        "value": "39"
                      },
                      {
                        "groupId": "BG002",
                        "value": "34"
                      },
                      {
                        "groupId": "BG003",
                        "value": "34"
                      },
                      {
                        "groupId": "BG004",
                        "value": "139"
                      }
                    ]
                  },
                  {
                    "title": "4 Severe",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "17"
                      },
                      {
                        "groupId": "BG001",
                        "value": "16"
                      },
                      {
                        "groupId": "BG002",
                        "value": "14"
                      },
                      {
                        "groupId": "BG003",
                        "value": "14"
                      },
                      {
                        "groupId": "BG004",
                        "value": "61"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Baseline Body Surface Area involved",
            "description": "Percentage of the subject's total body surface area (BSA) that is involved by lesions of plaque psoriasis .\n\nPercentage of total BSA involved by psoriasis lesions at Baseline",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "percentage",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "22.90",
                        "spread": "13.324"
                      },
                      {
                        "groupId": "BG001",
                        "value": "23.79",
                        "spread": "15.283"
                      },
                      {
                        "groupId": "BG002",
                        "value": "23.08",
                        "spread": "14.585"
                      },
                      {
                        "groupId": "BG003",
                        "value": "26.44",
                        "spread": "16.260"
                      },
                      {
                        "groupId": "BG004",
                        "value": "24.04",
                        "spread": "14.860"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Has Used Systemic Biologics?",
            "description": "Subjects who have used one or more systemic biologic treatment(s) for their plaque psoriasis in the past.\n\nThis information is collected at Screening/ Baseline Visit",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "No",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "32"
                      },
                      {
                        "groupId": "BG001",
                        "value": "34"
                      },
                      {
                        "groupId": "BG002",
                        "value": "30"
                      },
                      {
                        "groupId": "BG003",
                        "value": "35"
                      },
                      {
                        "groupId": "BG004",
                        "value": "131"
                      }
                    ]
                  },
                  {
                    "title": "Yes",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "17"
                      },
                      {
                        "groupId": "BG001",
                        "value": "21"
                      },
                      {
                        "groupId": "BG002",
                        "value": "18"
                      },
                      {
                        "groupId": "BG003",
                        "value": "13"
                      },
                      {
                        "groupId": "BG004",
                        "value": "69"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Body Weight",
            "description": "Subject's body weight as of Baseline Visit",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "kilograms",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "95.22",
                        "spread": "25.710"
                      },
                      {
                        "groupId": "BG001",
                        "value": "101.68",
                        "spread": "26.142"
                      },
                      {
                        "groupId": "BG002",
                        "value": "101.08",
                        "spread": "27.207"
                      },
                      {
                        "groupId": "BG003",
                        "value": "97.08",
                        "spread": "25.136"
                      },
                      {
                        "groupId": "BG004",
                        "value": "98.85",
                        "spread": "26.007"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "\u2022 The Percent Change in PASI (Psoriasis Area and Severity Index) Score From Baseline",
            "description": "The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.",
            "populationDescription": "modified Intent-to-Treat population Observed cases analysis",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "percentage change from baseline",
            "timeFrame": "12 Weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "XP23829 400 mg QD (Once Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period\n\nXP23829 400 mg QD: active dose 1"
              },
              {
                "id": "OG001",
                "title": "XP23829 800 mg QD (Once Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period\n\nXP 23829 800 mg QD: active dose 2"
              },
              {
                "id": "OG002",
                "title": "XP23829 400 mg BID (Twice Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period\n\nXP23829 400 mg BID: active dose 3"
              },
              {
                "id": "OG003",
                "title": "Placebo",
                "description": "After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks\n\nPlacebo: control"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "48"
                  },
                  {
                    "groupId": "OG001",
                    "value": "53"
                  },
                  {
                    "groupId": "OG002",
                    "value": "46"
                  },
                  {
                    "groupId": "OG003",
                    "value": "47"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-38.1",
                        "spread": "5.07"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-48.2",
                        "spread": "5.06"
                      },
                      {
                        "groupId": "OG002",
                        "value": "-50.7",
                        "spread": "5.50"
                      },
                      {
                        "groupId": "OG003",
                        "value": "-25.0",
                        "spread": "5.06"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG003"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.066",
                "statisticalMethod": "Mixed Models Analysis",
                "statisticalComment": "Restricted Maximum Likelihood (REML) - an REML-based mixed model for repeated measures (MMRM) with and with baseline PASI score as covariate"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG003"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.001",
                "statisticalMethod": "Mixed Models Analysis",
                "statisticalComment": "Restricted Maximum Likelihood (REML) - an REML-based mixed model for repeated measures (MMRM) with and with baseline PASI score as covariate"
              },
              {
                "groupIds": [
                  "OG002",
                  "OG003"
                ],
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "<0.001",
                "statisticalMethod": "Mixed Models Analysis",
                "statisticalComment": "Restricted Maximum Likelihood (REML) - an REML-based mixed model for repeated measures (MMRM) with and with baseline PASI score as covariate"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "\u2022 Proportion of Subjects Who Achieve a Reduction of 75% or Greater From Baseline in PASI (PASI-75)",
            "description": "The percentage of subjects who achieve a reduction of 75% or greater from Baseline in the Psoriasis Area and Severity Index score (PASI-75) at efficacy assessments conducted at Weeks 2, 4, 8, 12, 14 and 16. The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.",
            "populationDescription": "modified Intent-to-treat population with last observation carried forward imputation for missing values",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Weeks 2, 4, 8, 12, 14 and 16",
            "groups": [
              {
                "id": "OG000",
                "title": "XP23829 400 mg QD (Once Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period\n\nXP23829 400 mg QD: active dose 1"
              },
              {
                "id": "OG001",
                "title": "XP23829 800 mg QD (Once Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period\n\nXP 23829 800 mg QD: active dose 2"
              },
              {
                "id": "OG002",
                "title": "XP23829 400 mg BID (Twice Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period\n\nXP23829 400 mg BID: active dose 3"
              },
              {
                "id": "OG003",
                "title": "Placebo",
                "description": "After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks\n\nPlacebo: control"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "48"
                  },
                  {
                    "groupId": "OG001",
                    "value": "53"
                  },
                  {
                    "groupId": "OG002",
                    "value": "46"
                  },
                  {
                    "groupId": "OG003",
                    "value": "47"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "46"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "43"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      },
                      {
                        "groupId": "OG003",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "44"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "2"
                      },
                      {
                        "groupId": "OG003",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 8",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "44"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      },
                      {
                        "groupId": "OG002",
                        "value": "5"
                      },
                      {
                        "groupId": "OG003",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 12",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "44"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "7"
                      },
                      {
                        "groupId": "OG002",
                        "value": "10"
                      },
                      {
                        "groupId": "OG003",
                        "value": "4"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 14",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "48"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "47"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "6"
                      },
                      {
                        "groupId": "OG001",
                        "value": "4"
                      },
                      {
                        "groupId": "OG002",
                        "value": "6"
                      },
                      {
                        "groupId": "OG003",
                        "value": "3"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 16",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "48"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "47"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "3"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3"
                      },
                      {
                        "groupId": "OG002",
                        "value": "6"
                      },
                      {
                        "groupId": "OG003",
                        "value": "2"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG003"
                ],
                "groupDescription": "Week 12 comparison",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.501",
                "statisticalMethod": "Regression, Logistic"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG003"
                ],
                "groupDescription": "Week 12 comparison",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.340",
                "statisticalMethod": "Regression, Logistic"
              },
              {
                "groupIds": [
                  "OG002",
                  "OG003"
                ],
                "groupDescription": "Week 12 comparison",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.075",
                "statisticalMethod": "Regression, Logistic"
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "\u2022 Proportion of Subjects Who Achieve a sPGA (Static Physician's Global Assessment) Score of Clear or Almost Clear",
            "description": "The Percentage of subjects who achieve the static Physician's Global Assessment (sPGA) score of 'clear' or 'almost clear' (sPGA score 0 or 1) at efficacy assessments conducted at Weeks 2, 4, 8, 12, 14 and 16.\n\nScore Grade : Definition - 0 Clear: No signs of psoriasis\n\n1. Almost clear: No thickening to minimal plaque elevation; Normal to slight pink coloration/faint erythema; Focal to minimal scaling\n2. Mild: Slight elevation/thickening; Pink to light red coloration; Predominantly fine scaling partially or mostly covering lesions\n3. Moderate: Clearly distinguishable/distinct thickening; Definite red coloration; Coarse scaling covering most plaques\n4. Severe: Marked thickening with hard/sharp edges; Bright to deep dark red coloration; Thick/coarse scaling covering almost all or all lesions\n\nA lower score on this scale at the end of the study indicates an improvement in the disease condition.",
            "populationDescription": "modified 'Intent-to-treat' population using Last Observation Carried Forward method to impute missing observations",
            "reportingStatus": "POSTED",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "timeFrame": "Weeks 2, 4, 8, 12, 14 and 16",
            "groups": [
              {
                "id": "OG000",
                "title": "XP23829 400 mg QD (Once Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period\n\nXP23829 400 mg QD: active dose 1"
              },
              {
                "id": "OG001",
                "title": "XP23829 800 mg QD (Once Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period\n\nXP 23829 800 mg QD: active dose 2"
              },
              {
                "id": "OG002",
                "title": "XP23829 400 mg BID (Twice Daily)",
                "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period\n\nXP23829 400 mg BID: active dose 3"
              },
              {
                "id": "OG003",
                "title": "Placebo",
                "description": "After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks\n\nPlacebo: control"
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "48"
                  },
                  {
                    "groupId": "OG001",
                    "value": "53"
                  },
                  {
                    "groupId": "OG002",
                    "value": "46"
                  },
                  {
                    "groupId": "OG003",
                    "value": "47"
                  }
                ]
              }
            ],
            "classes": [
              {
                "title": "Week 2",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "46"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "43"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "0"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      },
                      {
                        "groupId": "OG003",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 4",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "44"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "1"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1"
                      },
                      {
                        "groupId": "OG002",
                        "value": "0"
                      },
                      {
                        "groupId": "OG003",
                        "value": "0"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 8",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "44"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "2"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      },
                      {
                        "groupId": "OG002",
                        "value": "1"
                      },
                      {
                        "groupId": "OG003",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 12",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "47"
                      },
                      {
                        "groupId": "OG001",
                        "value": "50"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "44"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "3"
                      },
                      {
                        "groupId": "OG002",
                        "value": "3"
                      },
                      {
                        "groupId": "OG003",
                        "value": "2"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 14",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "48"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "47"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "2"
                      },
                      {
                        "groupId": "OG002",
                        "value": "3"
                      },
                      {
                        "groupId": "OG003",
                        "value": "1"
                      }
                    ]
                  }
                ]
              },
              {
                "title": "Week 16",
                "denoms": [
                  {
                    "units": "Participants",
                    "counts": [
                      {
                        "groupId": "OG000",
                        "value": "48"
                      },
                      {
                        "groupId": "OG001",
                        "value": "53"
                      },
                      {
                        "groupId": "OG002",
                        "value": "46"
                      },
                      {
                        "groupId": "OG003",
                        "value": "47"
                      }
                    ]
                  }
                ],
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5"
                      },
                      {
                        "groupId": "OG001",
                        "value": "1"
                      },
                      {
                        "groupId": "OG002",
                        "value": "4"
                      },
                      {
                        "groupId": "OG003",
                        "value": "1"
                      }
                    ]
                  }
                ]
              }
            ],
            "analyses": [
              {
                "groupIds": [
                  "OG000",
                  "OG003"
                ],
                "groupDescription": "Week 12 comparison",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.229",
                "statisticalMethod": "Regression, Logistic"
              },
              {
                "groupIds": [
                  "OG001",
                  "OG003"
                ],
                "groupDescription": "Week 12 comparison",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.604",
                "statisticalMethod": "Regression, Logistic"
              },
              {
                "groupIds": [
                  "OG002",
                  "OG003"
                ],
                "groupDescription": "Week 12 comparison",
                "nonInferiorityType": "SUPERIORITY",
                "pValue": "0.573",
                "statisticalMethod": "Regression, Logistic"
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "5",
        "timeFrame": "Baseline to Week 16 or study discontinuation",
        "description": "Adverse Events are reported in the safety population ( which is identical to the randomized subject and intent-to treat populations)",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "XP23829 400 mg QD (Once Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period\n\nXP23829 400 mg QD: active dose 1",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 49,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 49,
            "otherNumAffected": 36,
            "otherNumAtRisk": 49
          },
          {
            "id": "EG001",
            "title": "XP23829 800 mg QD (Once Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period\n\nXP 23829 800 mg QD: active dose 2",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 55,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 55,
            "otherNumAffected": 42,
            "otherNumAtRisk": 55
          },
          {
            "id": "EG002",
            "title": "XP23829 400 mg BID (Twice Daily)",
            "description": "After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period\n\nXP23829 400 mg BID: active dose 3",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 48,
            "seriousNumAffected": 1,
            "seriousNumAtRisk": 48,
            "otherNumAffected": 37,
            "otherNumAtRisk": 48
          },
          {
            "id": "EG003",
            "title": "Placebo",
            "description": "After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks\n\nPlacebo: control",
            "deathsNumAffected": 0,
            "deathsNumAtRisk": 48,
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 48,
            "otherNumAffected": 29,
            "otherNumAtRisk": 48
          }
        ],
        "seriousEvents": [
          {
            "term": "Abdominal Adhesions",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Abdominal hernia",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Small intestinal obstruction",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Enterocolitis",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Cholecystitis acute",
            "organSystem": "Hepatobiliary disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          }
        ],
        "otherEvents": [
          {
            "term": "Diarrhea",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 11,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 22,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 19,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 7,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Nausea",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 6,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 4,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 10,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 6,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Abdominal pain",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 7,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 11,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 2,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Flushing",
            "organSystem": "Vascular disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 4,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 3,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 2,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 3,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Headache",
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 2,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 3,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 5,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 2,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Vomiting",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 3,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 7,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 1,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 1,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Abdominal pain upper",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 3,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 2,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 3,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 2,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Flatulence",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 2,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 5,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 3,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Nasopharyngitis",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 4,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 2,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 2,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Pruritus",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 3,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 2,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 3,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 1,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Dyspepsia",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 2,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 2,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 3,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 1,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Arthralgia",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 1,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 3,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 2,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 1,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Constipation",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 2,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 4,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Eosinophilia",
            "organSystem": "Blood and lymphatic system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 0,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 4,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 2,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Gastroesophageal reflux disease",
            "organSystem": "Gastrointestinal disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 3,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 0,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 1,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 2,
                "numAtRisk": 48
              }
            ]
          },
          {
            "term": "Paraesthesia",
            "organSystem": "Nervous system disorders",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numAffected": 0,
                "numAtRisk": 49
              },
              {
                "groupId": "EG001",
                "numAffected": 3,
                "numAtRisk": 55
              },
              {
                "groupId": "EG002",
                "numAffected": 0,
                "numAtRisk": 48
              },
              {
                "groupId": "EG003",
                "numAffected": 0,
                "numAtRisk": 48
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictionType": "OTHER",
          "restrictiveAgreement": true,
          "otherDetails": "Any publication would have to be collaborative effort between Sponsor and Investigators"
        },
        "pointOfContact": {
          "title": "Dr. Srinivas Shenoy B.,",
          "organization": "Dr Reddy's Laboratories Ltd.",
          "email": "srinivassshenoyb@drreddys.com",
          "phone": "49002900"
        }
      }
    },
    "studyId": "NCT02173301"
  },
  {
    "resultsSection": {
      "participantFlowModule": {
        "preAssignmentDetails": "Participants were randomized to ixekizumab (ixe) 80 mg Q2W or Q4W during the Induction Dosing Period from Week 0 to Week 12. Participants received ixe Q4W in the Maintenance Dosing Period from Week 12 to Week 48, and then to the Post Follow up Treatment Period for at least 12 weeks.",
        "recruitmentDetails": "Induction Dosing Period (Weeks 0 up to 12), Maintenance Dosing Period (Weeks 12 up to 48), Minimum Post Treatment Follow-Up Period up to 12 weeks after last visit.",
        "groups": [
          {
            "id": "FG000",
            "title": "Ixekizumab Q2W",
            "description": "160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
          },
          {
            "id": "FG001",
            "title": "Ixekizumab Q4W",
            "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44."
          }
        ],
        "periods": [
          {
            "title": "Induction Dosing Period",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "6"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "6"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "6"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "6"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "0"
                  }
                ]
              }
            ]
          },
          {
            "title": "Maintenance Dosing Period",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "comment": "All participants from Induction Dosing Period went to ixe Q4W arm during Maintenance Dosing Period.",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "12"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "12"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "0"
                  }
                ]
              }
            ]
          },
          {
            "title": "Post-Treatment Follow-up",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "12"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "12"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "0"
                  },
                  {
                    "groupId": "FG001",
                    "numSubjects": "0"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Ixekizumab Q2W",
            "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
          },
          {
            "id": "BG001",
            "title": "Ixekizumab Q4W",
            "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
          },
          {
            "id": "BG002",
            "title": "Total",
            "description": "Total of all reporting groups"
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "groupId": "BG000",
                "value": "6"
              },
              {
                "groupId": "BG001",
                "value": "6"
              },
              {
                "groupId": "BG002",
                "value": "12"
              }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "41.8",
                        "spread": "12.54"
                      },
                      {
                        "groupId": "BG001",
                        "value": "55.2",
                        "spread": "7.39"
                      },
                      {
                        "groupId": "BG002",
                        "value": "48.5",
                        "spread": "12.03"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "3"
                      },
                      {
                        "groupId": "BG002",
                        "value": "4"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      },
                      {
                        "groupId": "BG001",
                        "value": "3"
                      },
                      {
                        "groupId": "BG002",
                        "value": "8"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Ethnicity (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "2"
                      },
                      {
                        "groupId": "BG002",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Not Hispanic or Latino",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "5"
                      },
                      {
                        "groupId": "BG001",
                        "value": "4"
                      },
                      {
                        "groupId": "BG002",
                        "value": "9"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Race (NIH/OMB)",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "American Indian or Alaska Native",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Asian",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "1"
                      }
                    ]
                  },
                  {
                    "title": "Native Hawaiian or Other Pacific Islander",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Black or African American",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "1"
                      },
                      {
                        "groupId": "BG001",
                        "value": "1"
                      },
                      {
                        "groupId": "BG002",
                        "value": "2"
                      }
                    ]
                  },
                  {
                    "title": "White",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "4"
                      },
                      {
                        "groupId": "BG001",
                        "value": "5"
                      },
                      {
                        "groupId": "BG002",
                        "value": "9"
                      }
                    ]
                  },
                  {
                    "title": "More than one race",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  },
                  {
                    "title": "Unknown or Not Reported",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "0"
                      },
                      {
                        "groupId": "BG001",
                        "value": "0"
                      },
                      {
                        "groupId": "BG002",
                        "value": "0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "United States",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "6"
                      },
                      {
                        "groupId": "BG001",
                        "value": "6"
                      },
                      {
                        "groupId": "BG002",
                        "value": "12"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Time to at Least a 1 Point Improvement on the Patient's Global Assessment of Disease Severity (PatGA) Score",
            "description": "The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 Numeric Rating Score (NRS) the severity of their psoriasis \"today\" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.",
            "populationDescription": "All randomized participants.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "90% Confidence Interval",
            "unitOfMeasure": "Days",
            "timeFrame": "Baseline through Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Ixekizumab Q2W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
              },
              {
                "id": "OG001",
                "title": "Ixekizumab Q4W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "6"
                  },
                  {
                    "groupId": "OG001",
                    "value": "6"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "5.0",
                        "lowerLimit": "2.0",
                        "upperLimit": "5.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "6.0",
                        "lowerLimit": "4.0",
                        "upperLimit": "7.0"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Mean Change From Baseline on Itch Numeric Rating Scale (NRS) Score",
            "description": "The Itch NRS is a patient-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing \"no itch\" and 10 representing \"worst itch imaginable.\" Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Least Square Means (LS means) are from analysis of mixed-effects model for repeated measures (MMRM) and model includes treatment group, baseline value and timepoint.",
            "populationDescription": "All randomized participants.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Baseline, Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Ixekizumab Q2W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
              },
              {
                "id": "OG001",
                "title": "Ixekizumab Q4W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "6"
                  },
                  {
                    "groupId": "OG001",
                    "value": "6"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-6.2",
                        "spread": "0.53"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-6.6",
                        "spread": "0.55"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Mean Change From Baseline on the Dermatology Life Quality Index (DLQI)",
            "description": "The DLQI is a simple, patient-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include \"Not at all,\" \"A little,\" \"A lot,\" and \"Very much,\" with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of \"Not relevant\" which is scored as \"0\". For all questions, if unanswered the question is scored as \"0\". Totals range from 0 to 30 (less to more impairment). LS means are from analysis of MMRM and model includes treatment group, baseline value and timepoint.",
            "populationDescription": "All randomized participants.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Baseline, Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Ixekizumab Q2W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
              },
              {
                "id": "OG001",
                "title": "Ixekizumab Q4W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "6"
                  },
                  {
                    "groupId": "OG001",
                    "value": "6"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-13.4",
                        "spread": "1.56"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-14.3",
                        "spread": "1.59"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Mean Change From Baseline in Percent Body Surface Area (%BSA)",
            "description": "The BSA is the percentage involvement of psoriasis on each participant's body surface on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including the palm, fingers, and thumb). The total BSA affected was the summation of individual regions affected. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction",
            "populationDescription": "All randomized participants.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "percentage of body surface area",
            "timeFrame": "Baseline, Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Ixekizumab Q2W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
              },
              {
                "id": "OG001",
                "title": "Ixekizumab Q4W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "6"
                  },
                  {
                    "groupId": "OG001",
                    "value": "6"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-26.1",
                        "spread": "1.39"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-28.0",
                        "spread": "1.39"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Mean Change From Baseline on the Psoriasis Area and Severity Index (PASI)",
            "description": "The PASI combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation (scaling), erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in PASI scores compared to baseline. LS means are from analysis of MMRM and the model includes treatment group, baseline value, visit and treatment-by-visit interaction.",
            "populationDescription": "All randomized participants.",
            "reportingStatus": "POSTED",
            "paramType": "LEAST_SQUARES_MEAN",
            "dispersionType": "Standard Error",
            "unitOfMeasure": "units on a scale",
            "timeFrame": "Baseline, Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Ixekizumab Q2W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
              },
              {
                "id": "OG001",
                "title": "Ixekizumab Q4W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "6"
                  },
                  {
                    "groupId": "OG001",
                    "value": "6"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "-22.00",
                        "spread": "0.456"
                      },
                      {
                        "groupId": "OG001",
                        "value": "-22.72",
                        "spread": "0.456"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "type": "SECONDARY",
            "title": "Time to at Least a 2 Point Improvement on the PatGA Score",
            "description": "The PatGA is a patient-administered single-item scale on which participants are asked to rank by selecting a number on a 0 to 5 NRS the severity of their psoriasis \"today\" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been.",
            "populationDescription": "All randomized participants.",
            "reportingStatus": "POSTED",
            "paramType": "MEDIAN",
            "dispersionType": "90% Confidence Interval",
            "unitOfMeasure": "Days",
            "timeFrame": "Baseline though Week 12",
            "groups": [
              {
                "id": "OG000",
                "title": "Ixekizumab Q2W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44."
              },
              {
                "id": "OG001",
                "title": "Ixekizumab Q4W",
                "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "6"
                  },
                  {
                    "groupId": "OG001",
                    "value": "6"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "10.0",
                        "lowerLimit": "6.0",
                        "upperLimit": "12.0"
                      },
                      {
                        "groupId": "OG001",
                        "value": "13.5",
                        "lowerLimit": "5.0",
                        "upperLimit": "22.0"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "0",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Ixekizumab Q2W Induction Dosing Period",
            "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q2W through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.",
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 6,
            "otherNumAffected": 5,
            "otherNumAtRisk": 6
          },
          {
            "id": "EG001",
            "title": "Ixekizumab Q4W Induction Dosing Period",
            "description": "160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once Q4W through week 44.",
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 6,
            "otherNumAffected": 5,
            "otherNumAtRisk": 6
          },
          {
            "id": "EG002",
            "title": "Ixekizumab 80 mg Q4W Maintenance",
            "description": "After week 12 all participants are given 80 mg ixekizumab as a single SC injection once Q4W through week 44.",
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 12,
            "otherNumAffected": 9,
            "otherNumAtRisk": 12
          },
          {
            "id": "EG003",
            "title": "Ixekizumab 80 mg Q4W Post-treatment",
            "description": "All participants receiving at least one dose of ixekizumab entered the post treatment follow-up period for a minimum of 12 weeks.",
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 12,
            "otherNumAffected": 1,
            "otherNumAtRisk": 12
          }
        ],
        "otherEvents": [
          {
            "term": "Diarrhoea",
            "organSystem": "Gastrointestinal disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 2,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Toothache",
            "organSystem": "Gastrointestinal disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Fatigue",
            "organSystem": "General disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Injection site erythema",
            "organSystem": "General disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 3,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Injection site urticaria",
            "organSystem": "General disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Cellulitis",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Hordeolum",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Influenza",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Localised infection",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Skin bacterial infection",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Upper respiratory tract infection",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 4,
                "numAffected": 4,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Biopsy breast",
            "organSystem": "Investigations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Biopsy prostate",
            "organSystem": "Investigations",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 5
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 3
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 8
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 8
              }
            ]
          },
          {
            "term": "Arthralgia",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 2,
                "numAffected": 2,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Muscle spasms",
            "organSystem": "Musculoskeletal and connective tissue disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Acne",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Hyperhidrosis",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Pruritus",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 1,
                "numAffected": 1,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          },
          {
            "term": "Eye laser surgery",
            "organSystem": "Surgical and medical procedures",
            "sourceVocabulary": "MedDRA 19.0",
            "assessmentType": "SYSTEMATIC_ASSESSMENT",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG001",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 6
              },
              {
                "groupId": "EG002",
                "numEvents": 2,
                "numAffected": 1,
                "numAtRisk": 12
              },
              {
                "groupId": "EG003",
                "numEvents": 0,
                "numAffected": 0,
                "numAtRisk": 12
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictionType": "GT60",
          "restrictiveAgreement": true
        },
        "pointOfContact": {
          "title": "Chief Medical Officer",
          "organization": "Eli Lilly and Company",
          "phone": "800-545-5979"
        }
      }
    },
    "studyId": "NCT02387801"
  },
  {
    "resultsSection": {
      "participantFlowModule": {
        "groups": [
          {
            "id": "FG000",
            "title": "Infliximab 5 mg/kg",
            "description": "Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22."
          }
        ],
        "periods": [
          {
            "title": "Overall Study",
            "milestones": [
              {
                "type": "STARTED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "22"
                  }
                ]
              },
              {
                "type": "COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "comment": "Completed protocol at Week 24",
                    "numSubjects": "19"
                  }
                ]
              },
              {
                "type": "NOT COMPLETED",
                "achievements": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "3"
                  }
                ]
              }
            ],
            "dropWithdraws": [
              {
                "type": "Protocol Violation",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "2"
                  }
                ]
              },
              {
                "type": "Withdrawal by Subject",
                "reasons": [
                  {
                    "groupId": "FG000",
                    "numSubjects": "1"
                  }
                ]
              }
            ]
          }
        ]
      },
      "baselineCharacteristicsModule": {
        "groups": [
          {
            "id": "BG000",
            "title": "Infliximab 5 mg/kg",
            "description": "Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22."
          }
        ],
        "denoms": [
          {
            "units": "Participants",
            "counts": [
              {
                "groupId": "BG000",
                "value": "22"
              }
            ]
          }
        ],
        "measures": [
          {
            "title": "Age, Continuous",
            "paramType": "MEAN",
            "dispersionType": "STANDARD_DEVIATION",
            "unitOfMeasure": "years",
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "37.05",
                        "spread": "13.15"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Sex: Female, Male",
            "paramType": "COUNT_OF_PARTICIPANTS",
            "unitOfMeasure": "Participants",
            "classes": [
              {
                "categories": [
                  {
                    "title": "Female",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "3"
                      }
                    ]
                  },
                  {
                    "title": "Male",
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "19"
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "title": "Region of Enrollment",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "classes": [
              {
                "title": "Middle East",
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "BG000",
                        "value": "22"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "outcomeMeasuresModule": {
        "outcomeMeasures": [
          {
            "type": "PRIMARY",
            "title": "Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10",
            "description": "PASI 75 response is defined as participants who achieved at least a 75% improvement in PASI score from Baseline to Week 10.\n\nThe PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 to 72 (the higher the number, the worse the disease).",
            "reportingStatus": "POSTED",
            "paramType": "NUMBER",
            "unitOfMeasure": "participants",
            "timeFrame": "10 weeks",
            "groups": [
              {
                "id": "OG000",
                "title": "Infliximab 5 mg/kg",
                "description": "Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22."
              }
            ],
            "denoms": [
              {
                "units": "Participants",
                "counts": [
                  {
                    "groupId": "OG000",
                    "value": "22"
                  }
                ]
              }
            ],
            "classes": [
              {
                "categories": [
                  {
                    "measurements": [
                      {
                        "groupId": "OG000",
                        "value": "16"
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      },
      "adverseEventsModule": {
        "frequencyThreshold": "5",
        "eventGroups": [
          {
            "id": "EG000",
            "title": "Infliximab 5 mg/kg",
            "description": "Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.",
            "seriousNumAffected": 0,
            "seriousNumAtRisk": 22,
            "otherNumAffected": 11,
            "otherNumAtRisk": 22
          }
        ],
        "otherEvents": [
          {
            "term": "vomiting",
            "organSystem": "Gastrointestinal disorders",
            "sourceVocabulary": "MedDRA (12.0)",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 22
              }
            ]
          },
          {
            "term": "pyrexia",
            "organSystem": "General disorders",
            "sourceVocabulary": "MedDRA (12.0)",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 5,
                "numAffected": 4,
                "numAtRisk": 22
              }
            ]
          },
          {
            "term": "tinea versicolour",
            "organSystem": "Infections and infestations",
            "sourceVocabulary": "MedDRA (12.0)",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 22
              }
            ]
          },
          {
            "term": "cough",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "sourceVocabulary": "MedDRA (12.0)",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 22
              }
            ]
          },
          {
            "term": "oropharyngeal pain",
            "organSystem": "Respiratory, thoracic and mediastinal disorders",
            "sourceVocabulary": "MedDRA (12.0)",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 3,
                "numAffected": 3,
                "numAtRisk": 22
              }
            ]
          },
          {
            "term": "psoriasis",
            "organSystem": "Skin and subcutaneous tissue disorders",
            "sourceVocabulary": "MedDRA (12.0)",
            "stats": [
              {
                "groupId": "EG000",
                "numEvents": 5,
                "numAffected": 3,
                "numAtRisk": 22
              }
            ]
          }
        ]
      },
      "moreInfoModule": {
        "certainAgreement": {
          "piSponsorEmployee": false,
          "restrictionType": "OTHER",
          "restrictiveAgreement": true,
          "otherDetails": "The PI agrees not to publish/publicly present any interim results of the Study without prior written consent of Sponsor. The PI further agrees to\n\nprovide 30 days written notice to Sponsor prior to submission for publication/presentation to allow Sponsor to review materials which report any results of the Study. Sponsor shall have the right to review/comment on\n\nany presentation, which include editorial rights to ensure protection of confidential information, accuracy, and fair balance."
        },
        "pointOfContact": {
          "title": "Senior Vice President, Global Clinical Development",
          "organization": "Merck Sharp & Dohme Corp.",
          "email": "ClinicalTrialsDisclosure@merck.com"
        }
      }
    },
    "studyId": "NCT00687362"
  },
  {
    "resultsSection": {},
    "studyId": "NCT00646191"
  }
]